JANX-007 is a fusion protein commercialized by Janux Therapeutics, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of JANX-007’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for JANX-007 is expected to reach an annual total of $72 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

JANX-007 Overview

JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. It is being developed based on Tumor Activated T Cell Engager (TRACTr) technology. It is administered through intravenous route.

Janux Therapeutics Overview

Janux Therapeutics (Janux) is a clinical-stage biopharmaceutical company that develops novel immunotherapies to treat cancer. The company’s novel proprietary platforms T cell engager (TRACTr), and tumor activated immunomodulator (TRACIr) facilitate the manufacturing of monoclonal antibodies that delivers drug candidates. Janux products pipeline includes JANX007 and JANX008 that target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR). The company product pipelines are used to treat colorectal cancer, head and neck cancer, non-small cell lung cancer, and other solid tumors. Janux is headquartered in San Diego, California, the U.S.
The company reported revenues of (US Dollars) US$8.1 million for the fiscal year ended December 2023 (FY2023), a decrease of 6.1% over FY2022. The operating loss of the company was US$73 million in FY2023, compared to an operating loss of US$67.1 million in FY2022. The net loss of the company was US$58.3 million in FY2023, compared to a net loss of US$63.1 million in FY2022.

For a complete picture of JANX-007’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.